Diabetic Macular Edema

View All

Pharma News for AbbVie, Oculis, AstraZeneca, Krystal Biotech, Alligator Biosciences
FDA Approves RINVOQ for Crohn’s Disease; FDA Approves Krystal Biotech’s Gene Therapy Vyjuvek; FDA Approves EPKINLY to Treat R/R DLBCL; FDA Orphan Drug Designation to Mitazalimab; Phase 3 Trial Result of OCS-01 Eye Drops; TAGRISSO® + Chemotherapy for the EGFR-mutated Advanced Lung Cancer

FDA Approves RINVOQ as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease AbbVie announced that the FDA had approved RINVOQ® (upadacitinib) for treating people with moderately to highly active Crohn's disease who have had an unsatisfactory response or intolerance to one or more TNF blockers. Thi...

Find More

Diabetic Macular Edema Market | Diabetic Macular Edema Drug Portfolio
Diabetic Macular Edema Therapy Market to Witness Significant Impact in the Foreseeable Future

Diabetes is a condition in which the blood glucose (blood sugar) level is abnormally high. Glucose, which is obtained from the food consumed, is the primary source of energy in the body. However, the excess glucose level in the blood can cause health issues over time and can lead to vision disorders like Diabetic R...

Find More

DelveInsight’s Metabolic disorders based Gene Therapy Reports

Gene Therapy to “reverse” Metabolic disorders! Metabolic disorders are collectively common, frequently severe and in many instances difficult or impossible to treat. Accordingly, there is a compelling need to explore novel therapeutic modalities, including gene therapy, and examine multiple phenotypes where the ri...

Find More